ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Mergers & Acquisitions

Umicore buys Evonik’s metathesis IP

by Alex Scott
July 19, 2019 | APPEARED IN VOLUME 97, ISSUE 29

Umicore will acquire Evonik Industries’ intellectual property for metathesis chemistry and cross-coupling catalysis for an undisclosed sum. Metathesis chemistry is suitable for making complex molecules required by pharmaceutical and fine chemical companies and more, Umicore says. The deal follows Umicore’s purchase of Materia’s olefin metathesis catalyst business in 2018 for $27 million. In 2017, Materia lost a legal case in the US against Evonik relating to the validity of its metathesis patents.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment